en
Scientific article
Open access
English

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Published inAnnals of oncology, vol. 16, no. 2, p. 282-288
Publication date2005
Abstract

To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination with capecitabine as first-line treatment of metastatic colorectal cancer.

Keywords
  • Adult
  • Aged
  • Antimetabolites, Antineoplastic/administration & dosage/adverse effects/therapeutic use
  • Antineoplastic Agents, Phytogenic/administration & dosage/adverse effects/therapeutic use
  • Camptothecin/administration & dosage/adverse effects/analogs & derivatives/therapeutic use
  • Colorectal Neoplasms/drug therapy/pathology
  • Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives/therapeutic use
  • Drug Administration Schedule
  • Female
  • Fluorouracil/analogs & derivatives
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Quality of Life
  • Treatment Outcome
Citation (ISO format)
BORNER, M M et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. In: Annals of oncology, 2005, vol. 16, n° 2, p. 282–288. doi: 10.1093/annonc/mdi047
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0923-7534
541views
238downloads

Technical informations

Creation08/20/2014 12:21:00 PM
First validation08/20/2014 12:21:00 PM
Update time03/14/2023 9:32:24 PM
Status update03/14/2023 9:32:24 PM
Last indexation01/16/2024 11:39:17 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack